Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada) + Lopinavir/ritonavir (kaletra) versus TDF-FTC (Truvada) + raltegravir (Isentress). A prospective, randomized, open clinical trial.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
Indications HIV infections
Focus Adverse reactions
Acronyms RAL-PEP

Most Recent Events

18 Mar 2016 Results published in the Journal of Antimicrobial Chemotherapy
25 May 2015 Status changed from recruiting to completed.
11 Apr 2012 Additional lead trial centre, investigator (Garcia Felipe, MD) identified as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight